<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04008849</url>
  </required_header>
  <id_info>
    <org_study_id>IMD-002</org_study_id>
    <nct_id>NCT04008849</nct_id>
  </id_info>
  <brief_title>A Follow-up Study in Patients With Inherited Metabolic Disorders (IMD) Who Underwent Hematopoietic Stem Cell Transplantation (HSCT) With MGTA-456</brief_title>
  <acronym>IMD-002</acronym>
  <official_title>A Follow-Up Study to Evaluate the Safety and Clinical Outcomes of Patients With Non-Malignant Disease Who Have Undergone Hematopoietic Stem Cell Transplantation With MGTA-456</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Magenta Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Magenta Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A follow-up study to evaluate the safety and clinical outcomes of patients with inherited&#xD;
      metabolic disorders (IMD) who have undergone hematopoietic stem cell transplantation (HSCT)&#xD;
      with MGTA-456&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a follow-up study to evaluate the long-term safety and efficacy outcomes of patients&#xD;
      with inherited metabolic disorders (IMDs) who received MGTA-456 for HSCT in the core study.&#xD;
      MGTA-456 is an expanded CD34+ cell therapy product candidate given after myeloablative&#xD;
      conditioning to induce rapid and sustained hematopoietic engraftment. In patients with&#xD;
      selected IMDs, transplant is expected to replace defective or missing protein, and preserve&#xD;
      neurodevelopment. Patients with Hurler syndrome (also referred to as mucopolysaccharidosis-1H&#xD;
      (MPS-1H)), cerebral adrenoleukodystrophy (cALD), metachromatic leukodystrophy (MLD) or&#xD;
      globoid cell leukodystrophy (GLD) enrolled in the core study will be eligible to participate&#xD;
      in this follow-up evaluation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to low enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">May 21, 2019</start_date>
  <completion_date type="Actual">October 8, 2020</completion_date>
  <primary_completion_date type="Actual">October 8, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of related adverse events</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of serious adverse events</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of late hematological graft failure</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of chronic graft versus host disease</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in cALD Neurologic Function Score over time</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects without gadolinium enhancement on MRI over time</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Alpha-iduronidase blood enzyme level (nmol/hr/mg) in Hurler patients</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Very long chain fatty acid blood level (ug/mL) in cALD patients</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3</enrollment>
  <condition>Inherited Metabolic Disorders (IMD)</condition>
  <arm_group>
    <arm_group_label>Subjects treated with MGTA-456</arm_group_label>
    <description>MGTA-456 is an investigational expanded CD34+ cell therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Safety and efficacy assessments</intervention_name>
    <description>Long term safety and clinical outcomes</description>
    <arm_group_label>Subjects treated with MGTA-456</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood mononuclear cells &amp; plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with an inherited metabolic disorder (IMD) that were treated with MGTA-456&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  An Institutional Review Board (IRB)/Independent Ethics Committee-approved written&#xD;
             informed consent form must be signed and dated by the patient or legal guardian. Study&#xD;
             assents will also be prepared for children and adolescents to review when applicable.&#xD;
&#xD;
          -  Patient completed an IMD study in the MGTA-456 program and was administered MGTA-456&#xD;
             for HSCT.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        â€¢Patients enrolled in an IMD study in the MGTA-456 program who did not receive MGTA-456 or&#xD;
        were withdrawn from the core study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul J Orchard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>July 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inherited Metabolic Disorders</keyword>
  <keyword>Hematopoietic Stem Cell Transplant</keyword>
  <keyword>MGTA-456</keyword>
  <keyword>Umbilical Cord Blood Transplant</keyword>
  <keyword>Hurler Syndrome</keyword>
  <keyword>Cerebral Adrenoleukodystrophy</keyword>
  <keyword>Globoid Cell Leukodystrophy</keyword>
  <keyword>Metachromatic Leukodystrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

